- RecruitingPHASE3
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is testing a new medicine, Pasritamig, for men with advanced prostate cancer that has spread and is no longer responding to hormone treatments. We want to see if Pasritamig helps men live longer compared to a dummy medicine, alongside their usual supportive care.
For: Metastatic Castration-resistant Prostatic NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE1
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
This study looks at new drug combinations for advanced prostate cancer. Researchers want to find the safest and most effective doses of new medicines and see how well they work together, sometimes with existing treatments, to help men with this type of cancer.
For: Prostatic NeoplasmsUnited States · France · Japan - RecruitingPHASE1
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
This study is looking at two new medicines, JNJ-78278343 and JNJ-95298177, to treat prostate cancer that has spread and is no longer responding to usual hormone treatments. We want to find the best dose and see how safe and effective this combination is.
For: Prostatic NeoplasmsUnited States · United Kingdom